← Eichor
Study identifier: NCT07693244 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Exosome Therapy for Male Androgenetic Alopecia

Condition: Androgenetic Alopecia (AGA)  ·  Sponsor: Zhang Han

PhasePhase 2
Planned participants120
Who can joinMale, 18 Years to 55 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn if local scalp injection of human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) can treat androgenetic alopecia (AGA) in male patients with AGA. The main question it aims to answer is: Does hUCMSC-Exos injection improve hair regrowth compared with placebo? Researchers will compare hUCMSC-Exos injection to placebo injection to see if hUCMSC-Exos leads to superior efficacy in hair follicle regeneration, as measured by changes in hair density, hair thickness, and patient-reported outcomes. Participants will: Receive randomized, double-blinded local scalp injections of either hUCMSC-Exos or placebo Attend scheduled follow-up visits for hair assessment and safety monitoring Undergo photography, trichoscopy, and complete quality-of-life or psychosocial burden questionnaires as applicable

This description comes directly from the study's public registry record.

Talk to the study team

Han Zhang  ·  18510009269  ·  zhang_han_0112@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

No.28 Fuxing RoadBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07693244